RESEARCH MONOGRAPH · KDC-MN-323

Anandamide (AEA)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

80/100

The original endocannabinoid, biology is foundational, in vitro tool more than anything else

Anandamide is foundational. Devane and Mechoulam isolated it in 1992 (Science paper, one of those era-defining moments in receptor biology), and basically opened up the entire endocannabinoid system as a research field. The ligand-side biology of CB1 and CB2 starts here.

Mechanism is well-mapped: high-affinity partial agonist at CB1, lower affinity at CB2, additional activity at TRPV1 at higher concentrations (which is interesting and not always emphasized enough). It's synthesized on demand from membrane phospholipids via NAPE-PLD (one of several routes, the field has gotten more complicated than the original picture), and rapidly degraded by FAAH, which is why FAAH inhibitors became such an attractive target class.

For research the main use case is in vitro and ex vivo cannabinoid pharmacology. Receptor binding assays, calcium signaling, CB1 functional assays. It's the natural ligand and you compare everything else to it. In vivo work is harder because of the FAAH problem: anandamide has a vanishingly short half-life in tissue (seconds-to-minutes), which means peripheral administration is mostly useless unless you co-administer a FAAH inhibitor.

Pharmacology realities for the bench: aqueous solubility is terrible (it's basically a fatty acid amide), you're dissolving in DMSO or ethanol or formulating in carrier proteins like BSA for cell work. Light-sensitive, oxidizes, doesnt store well at room temp. The pure compound needs to live at minus 80 under argon if you care about it being intact after a few months.

Sourcing: synthetic anandamide is widely available from the standard cannabinoid suppliers, purity by HPLC is the standard QC, you want >98% and ideally an NMR. Cost per mg is high relative to the small molecules but you're not using a lot.

What we like: foundational endocannabinoid pharmacology, irreplaceable for in vitro CB1 work, the TRPV1 dual-agonism is genuinely interesting for cross-talk experiments.

What we dont like is the impracticality of doing anything in vivo with it directly. For systemic effects you'd be much better off pharmacologically manipulating FAAH (URB597, PF-04457845) to raise endogenous anandamide tone rather than dosing the molecule itself.

Bench tool, not a candidate for animal pharmacology in its native form. Respect the history.

Evidence: 88
Mechanism: 92
Reliability: 85
Safety: 80
Sourcing: 80
Value: 60
Signal: 70
Staying power: 88

Plain-language summary Intrigue 70 / 100

Anandamide is one of the two main endocannabinoids, the cannabis-like molecules your own brain makes. The name comes from the Sanskrit word for bliss, chosen by the Mechoulam lab that isolated it in 1992. It is built on demand from membrane phospholipids, activates the same CB1 receptors that THC engages, and is then quickly broken down by the FAAH enzyme. The transient nature of its signaling has been linked to mood, pain processing, exercise-induced euphoria (the runner's high may be more anandamide than endorphin), and reward. Most therapeutic interest lies not in giving anandamide directly but in blocking FAAH to raise the levels your body already produces. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Endocannabinoid (N-arachidonoylethanolamine)

The principal endogenous CB1 receptor agonist; a fatty acid amide neurotransmitter implicated in mood, pain, and reward.

Abstract

Anandamide (N-arachidonoylethanolamine, AEA; CAS 94421-68-8; molecular formula C22H37NO2; molecular weight 347.53) is the principal endogenous CB1 receptor agonist, isolated by Devane and Mechoulam in 1992 (Nature). The name derives from the Sanskrit ananda (bliss). The compound is synthesized on-demand from membrane phospholipid precursors via NAPE-PLD and degraded primarily by fatty acid amide hydrolase (FAAH); the on-demand synthesis-degradation kinetics produce highly localized signaling without the persistent receptor occupation typical of conventional neurotransmitters. CB1 affinity is approximately 89 nM with full agonist activity; secondary TRPV1 and PPAR-gamma activity. Plasma half-life is on the order of minutes, extremely short owing to rapid FAAH-mediated degradation. Used as the canonical endocannabinoid in academic neuroscience and as a substrate in FAAH inhibitor research. The administration of exogenous anandamide as a drug is impractical owing to the short half-life; FAAH inhibitors (URB597, PF-04457845) are used to elevate endogenous anandamide instead.

Mechanism of action

Endogenous full agonist at CB1 receptors; secondary TRPV1 and PPAR-gamma activity. Rapid on-demand synthesis and FAAH-mediated degradation.

Reported research dose ranges

Research substrate; in vitro and in vivo experimental concentrations vary.

References

Devane WA, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992.
Cravatt BF, et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996.
Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-323

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Anandamide (AEA)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs